Introduction: Genetic polymorphisms in codons 10 of the transforming growth factor β1 (TGF-β1) gene TGFB1 have been shown to be associated with the production of high or low TGF-β1 levels. The role of this polymorphism in the development of prostate cancer and hyperplasia was investigated. Subjects and Methods: Using the allele-specific oligonucleotide polymerase chain reaction method, the association between the polymorphism at codon 10 of the TGFB1 gene and the risk of prostate cancer (PCa) or benign prostate hyperplasia (BPH) was determined. Results: Significant differences in the CC versus TT genotype distribution between PCa patients and male controls (p = 0.009), and between BPH patients and male controls (p = 0.005) were noted. Males with the TT genotype had a 1.67-fold increased risk of PCa and those with the TC/TT genotype had a 1.14-fold increased risk of PCa; males with the TT genotype had a 1.54-fold increased risk of BPH and those a with the TT/TC genotype had a 1.06-fold increased risk of BPH compared with those with the CC genotype. Conclusions: Based on our findings, it was possible to conclude that the codon 10 polymorphism in TGFB1 may have a significant influence on the development of PCa and BPH and that the T allele of the TGFB1 gene has a dominant effect on the development of PCa and BPH.

Keywords:
TGFB1 polymorphism, Prostate cancer, Hyperplasia
This content is only available via PDF.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.